1. Home
  2. CRF vs REPL Comparison

CRF vs REPL Comparison

Compare CRF & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

HOLD

Current Price

$5.80

Market Cap

999.4M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

BUY

Current Price

$11.62

Market Cap

1.3B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CRF
REPL
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
999.4M
1.3B
IPO Year
1997
2018

Fundamental Metrics

Financial Performance
Metric
CRF
REPL
Price
$5.80
$11.62
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $19.50
AVG Volume (30 Days)
1.2M
★ 1.9M
Earning Date
01-01-0001
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$497.81
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.82
$1.50
52 Week High
$8.16
$16.33

Technical Indicators

Market Signals
Indicator
CRF
REPL
Relative Strength Index (RSI) 30.50 41.75
Support Level N/A $6.81
Resistance Level $6.24 $12.50
Average True Range (ATR) 0.11 0.67
MACD -0.02 -0.05
Stochastic Oscillator 0.00 31.91

Price Performance

Historical Comparison
CRF
REPL

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: